Longer Interval to Surgery Associated with Poor DFS in Population With Poor Pathologic Response to Neoadjuvant CRT in Advanced Rectal Cancer

Article

Patients who had a poor pathological response to preoperative chemoradiation for advanced rectal cancer and waited 8 weeks or longer for surgery were likely to experience poor overall disease-free survival after completing neoadjuvant chemoradiotherapy.

Among those who experienced a poor pathologic response to neoadjuvant chemoradiation, a longer interval before surgery was associated with a worse disease-free survival (DFS) among patients with advanced rectal cancer, according to an article published in JAMA Surgery.

Patients who had a longer wait time of 8 weeks or more (45.6%) vs less than 8 weeks (54.4%) had a worse 5- year overall survival rate of 67.6% (95% CI, 63.1%-71.7%) compared with 80.3% (95% CI, 76.5%-83.6%). Additionally, the 2 groups had a 10-year overall survival rate of 40.1% (95% CI, 33.5%-46.5%) and 57.8% (95% CI, 52.1%-63.0%; P <.001), respectively. Patients whose surgery was delayed had a 5-year DFS of 59.6% (95% CI, 54.9%-63.9%) compared with 72.0% (95% CI, 67.9%-75.7%). Moreover, the 10-year DFS rates were 36.2% (95% CI, 29.9%-42.4%) and 53.9% (95% CI, 48.5%-59.1%; P <.001).

A total of 1064 patients were included in the analysis. The majority of the population were men (61.5%) and the median age was 64 years. The median waiting time for surgery was 7 weeks for the shorter interval group and 10.6 weeks for the longer interval group.

Waiting longer than 8 weeks for surgery was associated with significantly higher rates of abdominal perineal resections in (33.2%) compared with those who waited less than 8 weeks (21.9%; OR, 1.71; 95% CI, 1.3-2.2; P <.001). A longer interval before surgery was also associated with higher rates of positive circumferential resection margin (1.7% vs 0.5%; OR, 3.6; 95% CI, 1.1-12.4; P = .04), 30-day morbidity rates (19.6% vs 14.8%; OR, 1.4; 95% CI, 1.0-1.9; P = .04), and surgical complication rates (15.1% vs 10.0%; OR, 1.6; 95% CI, 1.1-2.3; P = .01).

The median follow-up was 63 months, during which 26.9% of patients had disease recurrence and 37.7% had died. A total of 7.5% of patients had local recurrence, 23.9% had distant recurrence, and 4.5% had both local and distant recurrence.

A longer interval prior to surgery was also associated with a significantly higher cumulative incidence of local recurrence at 5 years (10.4% [95% CI, 7.8%-13.7%] vs 5.3% [95% CI, 3.7%-7.7%]) and 10 years (13.4% [95% CI, 9.8%-18.2%] vs 7.1% [95% CI, 5.0%-10.2%]; P = .005). A similar association was identified with regard to distant recurrence at 5-years (25.5% [95% CI, 21.6%-29.9%] vs 20.8% [95% CI, 17.5%-24.6%]), and 10 years (32.9% [95% CI, 27.9%-38.5%] vs 28.4% [95% CI, 24.1%-33.3%]; P = .055).

The use of the Cox analysis confirmed that patients who waited longer for surgery had an independent association with a higher risk of death (HR, 1.84; 95% CI, 1.50-2.26; P <.001), and death or recurrence (HR, 1.69; 95% CI, 1.39-2.04; P<.001).

Reference

Deidda S, Elmore U, Rosati R, et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative chemoradiation. JAMA Surg. Published Online September 29, 2021. doi:10.1001/jamasurg.2021.4566

Related Videos
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
Stacey Cohen, MD, an expert on colorectal cancer
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
A panel of 5 experts on colorectal cancer
Aparna Parikh, MD, an expert on colorectal cancer